How should we proceed with disease-modifying treatments for multiple sclerosis?

被引:18
作者
Andersson, PB
Waubant, E
Goodkin, DE
机构
关键词
D O I
10.1016/S0140-6736(05)61562-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:586 / 587
页数:2
相关论文
共 7 条
[1]   HOW MANY PEOPLE IN THE WORLD HAVE MULTIPLE-SCLEROSIS [J].
DEAN, G .
NEUROEPIDEMIOLOGY, 1994, 13 (1-2) :1-7
[2]  
FISCHER JS, 1996, MULTIPLE SCLEROSIS A, P123
[3]   LOW-DOSE (7.5-MG) ORAL METHOTREXATE REDUCES THE RATE OF PROGRESSION IN CHRONIC PROGRESSIVE MULTIPLE-SCLEROSIS [J].
GOODKIN, DE ;
RUDICK, RA ;
MEDENDORP, SV ;
DAUGHTRY, MM ;
SCHWETZ, KM ;
FISCHER, J ;
VANDYKE, C .
ANNALS OF NEUROLOGY, 1995, 37 (01) :30-40
[4]  
JOHNSON KP, 1996, MULTIPLE SCLEROSIS A, P289
[5]  
KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
[6]  
LAROCCA NG, 1996, MULTIPLE SCLEROSIS A, P145
[7]  
Rudick R. A., 1996, MULTIPLE SCLEROSIS A, P223